"The voice for cancer physicians and their patients in Massachusetts."

  • Home
  • Resources
  • FDA Approvals
  • Foundation Medicine Expands Indication for FoundationOne®Liquid CDx to be Used as a Companion Diagnostic for TABRECTA® (capmatinib)

Foundation Medicine Expands Indication for FoundationOne®Liquid CDx to be Used as a Companion Diagnostic for TABRECTA® (capmatinib)

16 Jul 2021 7:00 AM | Katy Monaco (Administrator)
Food and Drug Administration approved FoundationOne Liquid CDx as a companion diagnotic for TABRECTA (capmatinib.) FoundationOne Liquide CDx is now approved to identify patients with MED exon 14 (METex14) skipping metastatic non-small cell lung cancer (NSCLC) who may be appropriate for treatment with TABRECTA (capmatinib). Press Release. July 15, 2021. Drug Information.

Massachusetts Society of Clinical Oncologists (c)


P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: msco@mms.org
Powered by Wild Apricot Membership Software